表紙
市場調査レポート

バイオテクノロジー・薬剤開発・ドラッグデリバリー分野におけるナノ粒子

Nanoparticles in Biotechnology, Drug Development and Drug Delivery

発行 BCC Research 商品コード 251476
出版日 ページ情報 英文 192 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
バイオテクノロジー・薬剤開発・ドラッグデリバリー分野におけるナノ粒子 Nanoparticles in Biotechnology, Drug Development and Drug Delivery
出版日: 2014年08月29日 ページ情報: 英文 192 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

バイオテクノロジー・医薬品分野におけるナノ粒子の世界市場は2013年に約250億米ドルに達しました。同市場は2014-2019年の間に年間複合成長率(CAGR)22.0%で成長し、2014年の296億米ドルから2019年には798億米ドルの規模に達すると予測されています。

当レポートでは、ライフサイエンス部門(バイオテクノロジー・薬剤開発および製剤・ドラッグデリバリー・画像診断)で用いられるナノ粒子の市場について調査分析し、ナノ粒子の構造とナノ粒子の製造方法、各部門におけるナノ粒子の主な用途と主な製品・薬剤の概要、市場規模実績・予測、市場成長推進因子・阻害因子の分析、ナノ粒子製剤のパイプライン動向、主要企業のプロファイルなどをまとめ、提供しています。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • ナノ粒子の概要
  • ナノ粒子の略歴
  • バイオテクノロジーにおけるナノ粒子
  • 薬剤開発におけるナノ粒子
  • ドラッグデリバリーシステムにおけるナノ粒子
  • 診断画像におけるナノ粒子
  • ナノ粒子ドラッグデリバリー分野における主要企業
  • 主なナノ粒子/ナノ結晶製剤の収益

第4章 ライフサイエンス部門におけるナノ粒子:世界市場

  • バイオテクノロジー部門におけるナノ粒子:世界市場
  • 薬剤開発部門におけるナノ粒子:世界市場
  • ドラッグデリバリーシステム部門におけるナノ粒子:世界市場
  • 診断画像部門におけるナノ粒子:世界市場
  • ナノバイオテクノロジー・ナノメディスン企業の世界における流通

第5章 ナノ粒子の構造

  • 応用市場へのナノ粒子の投入
  • ナノ粒子のドラッグデリバリー用途

第6章 ナノ粒子の製造

  • ナノ粒子の形成方法
  • セルフアセンブリー法
  • 安定化の手法
  • 薬剤導入の手法
  • ナノ粒子への生物学的分子のローディングの手法
  • ナノ結晶製剤
  • 大規模なナノ粒子製造に関する問題

第7章 バイオテクノロジーにおけるナノ粒子

  • R&D
  • 肝細胞研究
  • 細胞修復
  • インビトロイメージング
  • 常磁性・超常磁性ナノ粒子
  • バイオセンサー・量子ドット
  • ナノ粒子研究共同プログラム

第8章 薬剤開発および製剤におけるナノ粒子

  • バイオセパレーション
  • 迅速薬剤分析
  • 不純物および毒素の除去
  • ナノ粒子を利用した不溶性薬物の取り入れ
  • バイオ医薬品における金および銀ナノ粒子
  • DNA特異的製剤のDNAナノ粒子の開発

第9章 ドラッグデリバリーシステムにおけるナノ粒子

  • ドラッグデリバリー用途におけるナノ粒子
  • ナノ粒子のドラッグデリバリーシステムの設計
  • ナノ粒子製剤の安定性
  • ナノ粒子製剤のサイズの均一性
  • ナノ粒子の薬剤装填
  • ナノ粒子からの薬剤放出
  • ナノ粒子からの薬剤放出:外的トリガー
  • 生物学的分子のナノ粒子へのバインディング/組み入れ
  • ナノ粒子の毒素
  • 大規模製造
  • 生物学的高分子ナノ粒子
  • ナノ結晶
  • 現在利用できるナノ粒子ドラッグデリバリーシステム
  • ナノ粒子からの抗がん剤の放出
  • ナノ粒子が伝達する生体高分子
  • ドラッグデリバリーシステム向けナノ粒子コーティング
  • 体内からのナノ粒子の除去

第10章 インビトロおよびインビボ診断画像

  • インビトロイメージング
  • 診断画像におけるナノ粒子

第11章 ナノ粒子の生物医学製品

  • 現在のFDA承認済みナノ粒子製剤
  • ナノ粒子のドラッグデリバリーシステムにおける主要企業
  • ナノ粒子ドラッグデリバリー企業のパイプライン
  • ナノ粒子製品とマーケティングの推進因子
  • ナノ粒子製品とマーケティングの阻害因子

第12章 ナノ粒子製剤・デリバリーシステムの世界市場

  • 世界市場

第13章 ナノ粒子製剤とドラッグデリバリーシステムの臨床試験

  • 前臨床段階にあるナノ粒子製剤

第14章 特許・ライセンス・M&A

  • ナノ粒子の特許
  • 米国特許:ナノ粒子製剤の開発
  • 米国特許:ナノ粒子製剤のデリバリー
  • 量子ドットの特許

第15章 企業プロファイル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO113B

The global market for nanoparticles in biotechnology and pharmaceuticals reached nearly $25.0 billion in 2013. This market is expected to reach $29.6 billion in 2014 and $79.8 billion in 2019, with a compound annual growth rate (CAGR) of 22.0% for the period of 2014 to 2019.

This report provides:

  • An overview of the global market for nanoparticles in biotechnology, drug development, and drug delivery.
  • Analyses of global market trends, with data from 2012 and 2013, estimates for 2014, and projections of CAGRs through 2019.
  • A review of existing drug products and potential drugs in the pipelines of the major pharmaceutical players in the market.
  • A look at how market growth is being driven in emerging geographies stemming from the health awareness of the growing middle class in countries such as India, China, Brazil and Russia.
  • Analysis of changing market dynamics, emerging players and products, strategies for accessing emerging markets, and analysis of specific disease prevalence.
  • Profiles of manufacturers of leading products and information on their specific products.

image1

REPORT SCOPE

SCOPE OF REPORT

Current and projected product forecasts during the forecast period of 2014 through 2019 are discussed. New product launches will be discussed. Revenue figures for 2013 are actual figures except where actual results have not been reported due to the timing of this report's release.

The report includes analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.

Market figures are based on revenues at the manufacturer level and are projected at 2013-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.

Included in this report are forecasts by product, product category and by company from 2012 through 2019. The study is arranged to offer an overview of existing nanoparticle technology and of drug markets; it is accompanied by nanoproduct, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country.

Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis unless specifically noted.

ANALYST'S CREDENTIALS

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early and mid-stage drug development.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, 2012-2019 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • NANOPARTICLE OVERVIEW
  • TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND DIAGNOSTIC IMAGING
    • LIPOSOMES
    • QUANTUM DOTS
    • DENDRIMERS
    • MACROMOLECULE NANOPARTICLES
  • BRIEF HISTORY OF NANOPARTICLES
  • NANOPARTICLES IN BIOTECHNOLOGY
  • TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY
  • NANOPARTICLES IN DRUG DEVELOPMENT
  • TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT
  • NANOPARTICLES IN DRUG DELIVERY SYSTEMS
  • TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS
  • TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS
  • NANOPARTICLES IN DIAGNOSTIC IMAGING
  • TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING
  • MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY FIELD
  • TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD
  • TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS, THROUGH 2019 ($ MILLIONS) 2
  • MAJOR NANOPARTICLE/NANOCRYSTAL DRUG REVENUES
  • TABLE 9 MAJOR NANOPARTICLE/NANOCRYSTAL DRUG REVENUES, THROUGH 2014

CHAPTER 4 GLOBAL MARKET FOR NANOPARTICLES IN LIFE SCIENCE

  • TABLE 10 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2019 ($ MILLIONS)
  • GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY
  • TABLE 11 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF NANOPARTICLES, THROUGH 2019 ($ MILLIONS)
  • GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT
  • TABLE 12 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION, THROUGH 2019 ($ MILLIONS)
  • GLOBAL MARKET FOR NANOPARTICLES IN DRUG DELIVERY SYSTEMS
  • TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS)
  • GLOBAL MARKET FOR NANOPARTICLES IN DIAGNOSTIC IMAGING
  • TABLE 14 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING SYSTEMS, THROUGH 2019 ($ MILLIONS)
  • GLOBAL DISTRIBUTION OF NANOBIOTECHNOLOGY AND NANOMEDICINE COMPANIES
  • TABLE 15 GLOBAL DISTRIBUTION OF NANOBIOTECHNOLOGY AND NANOMEDICINE COMPANIES

CHAPTER 5 NANOPARTICLES STRUCTURE

  • ADOPTION OF NANOPARTICLES IN APPLIED MARKETS
  • TABLE 16 NANOPARTICLE STRUCTURE AND PROPERTIES
    • LIQUID CRYSTALS
    • LIQUID CARRIERS
    • LIPOSOMES
    • DENDRIMERS
    • CHITOSAN AND ALGINATE
    • NANOCRYSTALS
    • QUANTUM DOTS
  • APPLICATION OF NANOPARTICLES TO DRUGS DELIVERED
  • TABLE 17 NANOPARTICLE SYSTEMS APPROVED FOR DRUG DELIVERY

CHAPTER 6 NANOPARTICLE PRODUCTION

  • METHOD OF NANOPARTICLE FORMATION
  • SELF-ASSEMBLY PRODUCTION
  • METHODS OF STABILIZATION
  • METHODS OF DRUG INTRODUCTION
    • POLYMERIC NANOPARTICLES
    • MICELLES
    • LIPOSOMES
    • TABLE 18 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME NANOTECHNOLOGY
    • GOLD AND SILICON NANOPARTICLES
    • DENDRIMERS
  • METHODS OF LOADING BIOLOGICAL MOLECULES INTO NANOPARTICLES
  • NANOCRYSTAL DRUGS
  • PROBLEMS WITH LARGE-SCALE NANOPARTICLE PRODUCTION

CHAPTER 7 NANOPARTICLES IN BIOTECHNOLOGY

  • TABLE 19 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS
  • RESEARCH AND DEVELOPMENT
  • STEM CELL RESEARCH
  • CELLULAR REPAIR
  • IN VITRO IMAGING
  • PARAMAGNETIC AND SUPERPARAMAGNETIC NANOPARTICLES
  • BIOSENSORS AND QUANTUM DOTS
    • QUANTUM DOTS
    • BIOSENSORS
    • TABLE 20 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT
  • NANOPARTICLE RESEARCH COLLABORATIVE PROGRAMS
  • TABLE 21 ETPN STRATEGIC RESEARCH AND INNOVATION AGENDA

CHAPTER 8 NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION

  • TABLE 22 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS
  • BIOSEPARATIONS
  • TABLE 23 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE IN NANOPARTICLE DELIVERY SYSTEMS
  • RAPID DRUG ANALYSIS
  • REMOVAL OF IMPURITIES AND TOXINS
  • USING NANOPARTICLES TO INCORPORATE INSOLUBLE DRUGS
  • TABLE 24 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS
  • GOLD AND SILVER NANOPARTICLES IN BIOMEDICINE
  • DNA NANOPARTICLE DEVELOPMENT OF DNA-SPECIFIC DRUGS

CHAPTER 9 NANOPARTICLES IN DRUG DELIVERY SYSTEMS

  • NANOPARTICLES IN DRUG DELIVERY APPLICATIONS
  • TABLE 25 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS
  • DESIGNING A NANOPARTICLE DRUG DELIVERY SYSTEM
  • NANOPARTICLE DRUG STABILITY
  • SIZE HOMOGENEITY OF NANOPARTICLE PREPARATIONS
  • DRUG LOADING OF NANOPARTICLES
  • DRUG RELEASE FROM NANOPARTICLE
  • EXTERNAL TRIGGERS FOR RELEASING DRUG FROM NANOPARTICLES 7
  • BINDING/INCORPORATION OF BIOMOLECULES TO NANOPARTICLES
  • NANOPARTICLE TOXICITY
  • LARGE-SCALE MANUFACTURING
    • METHODS OF ADMINISTRATION OF NANOPARTICLE DRUGS
    • TABLE 26 STANDARD ROUTES OF DRUG ADMINISTRATION
    • ORAL ADMINISTRATION
    • INJECTION ADMINISTRATION
    • TRANSDERMAL PATCH
    • TABLE 27 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS
    • IMPLANTATION ADMINISTRATION
    • INHALATION ADMINISTRATION
    • NANOPARTICLES SUITABLE FOR DRUG DELIVERY SYSTEMS
    • TABLE 28 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS
    • LIPID-BASED NANOPARTICLES
    • MICELLE NANOPARTICLES
    • DENDRIMER NANOPARTICLES
    • POLYMERIC NANOPARTICLES
    • METAL-BASED NANOPARTICLES
  • BIOLOGICAL MACROMOLECULE NANOPARTICLES
  • NANOCRYSTALS
  • TABLE 29 NANOCRYSTAL DRUGS APPROVED BY THE FDA
  • NANOPARTICLE DRUG DELIVERY SYSTEMS NOW AVAILABLE
    • ANTIBIOTIC NANOPARTICLES
    • ANTI-TUMOR AND SMALL MOLECULE DELIVERY BY NANOPARTICLE
  • RELEASE OF ANTI-CANCER DRUGS FROM NANOPARTICLES
  • BIOMACROMOLECULES DELIVERED BY NANOPARTICLES
  • NANOPARTICLE COATINGS FOR DRUG DELIVERY SYSTEMS
  • REMOVAL OF NANOPARTICLES FROM THE BODY
    • RENAL CLEARANCE
    • TABLE 30 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY

CHAPTER 10 IN VITRO AND IN VIVO DIAGNOSTIC IMAGING

  • IN VITRO IMAGING
  • NANOPARTICLES IN DIAGNOSTIC IMAGING
  • TABLE 31 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC IMAGING

CHAPTER 11 BIOMEDICAL NANOPARTICLE PRODUCTS

  • FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS AND PRODUCTS
  • TABLE 32 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS
  • TABLE 33 FDA-APPROVED DRUGS FOR CANCER TREATMENT
  • TABLE 34 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES
  • TABLE 35 FDA-APPROVED NANOPARTICLE DRUGS FOR INFECTIOUS DISEASES
  • MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY SYSTEMS
  • TABLE 36 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION MARKET
  • COMPANY PIPELINES FOR NANOPARTICLE DRUG DELIVERY
  • TABLE 37 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS
  • TABLE 38 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS
  • TABLE 39 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS
  • TABLE 40 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS
  • TABLE 41 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS
  • TABLE 42 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS
  • TABLE 43 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS
  • DRIVERS OF NANOPARTICLE PRODUCTS AND MARKETING
  • LIMITERS OF NANOPARTICLE PRODUCT DEVELOPMENT AND MARKETING

CHAPTER 12 GLOBAL MARKET FOR NANOPARTICLE DRUGS AND DELIVERY SYSTEMS

  • THE GLOBAL MARKET
  • TABLE 44 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS)
  • TABLE 45 REGIONAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS)
  • TABLE 46 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING, THROUGH 2019 ($ MILLIONS)

CHAPTER 13 CLINICAL TRIALS OF NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS

  • TABLE 47 DISTRIBUTION OF NANOPARTICLE DRUG CLINICAL TRIALS WITHIN DISEASE CATEGORIES
  • TABLE 48 CLINICAL TRIALS FOR NANOPARTICLE DRUGS FOR CANCER
  • TABLE 49 CLINICAL TRIALS FOR NANOPARTICLE DRUGS/PROCEDURES (NON-CANCER)
  • TABLE 50 CLINICAL TRIALS WITH NANOPARTICLE DRUGS (MISCELLANEOUS)
  • TABLE 51 RESPIRATORY SYNCYTIAL VIRUS NANOPARTICLE VACCINE CLINICAL TRIALS
  • TABLE 52 CLINICAL TRIALS FOR NANOPARTICLES FOR DIAGNOSTIC IMAGING
  • NANOPARTICLE DRUGS IN PRECLINICAL TESTING STAGE
  • TABLE 53 NANOPARTICLE DRUGS/CARRIERS IN PRECLINICAL EVALUATION

CHAPTER 14 PATENTS, LICENSING, MERGERS AND ACQUISITIONS

  • TABLE 54 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER AND ACQUISITION ACTIVITIES
  • NANOPARTICLE PATENTS
  • TABLE 55 GLOBAL PERCENTAGE OF PATENTS ISSUED BY GEOGRAPHY, THROUGH 2014
  • U.S. PATENTS FOR NANOPARTICLES DRUG DEVELOPMENT AND DELIVERY
  • TABLE 56 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT AND DELIVERY
  • TABLE 57 U.S. PATENTS FOR NANOCRYSTALLINE DRUGS
  • QUANTUM DOT PATENTS
  • TABLE 58 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICAL APPLICATIONS

CHAPTER 15 COMPANY PROFILES

  • ABRAXIS BIOSCIENCES, INC
    • PRODUCTS
    • STRATEGY
  • ACCESS PHARMA INC.
    • PRODUCTS
    • STRATEGY
  • ADVANCELL
    • STRATEGY
  • ALKERMES, PLC
    • PRODUCTS
    • STRATEGY
  • ALNYLAM PHARMACEUTICALS INC.
    • PRODUCTS
    • STRATEGY
  • AMAG PHARMACEUTICALS INC.
    • PRODUCTS
    • STRATEGY
  • ASTRAZENECA PHARMACEUTICALS, PLC
    • PRODUCTS
    • STRATEGY
  • BIND BOSCIENCES INC.
    • STRATEGY
  • CALGENE CORP.
    • STRATEGY
  • CAMURUS AB
    • STRATEGY
  • CAPSULATION AG
    • STRATEGY
  • CERAMISPHERE PTY LTD
    • STRATEGY
  • CERULEAN PHARMA INC.
    • STRATEGY
  • CYTIMMUNE SCIENCES
    • PRODUCTS
    • STRATEGY
  • DEBIOTECH, S.A.
    • PRODUCTS
    • STRATEGY
  • ELAN PHARMACEUTICALS INC.
    • PRODUCTS
    • STRATEGY
  • ENSEMBLE THERAPEUTICS
    • STRATEGY
  • FLAMEL TEHNOLOGIES, INC
    • PRODUCTS
    • STRATEGY
  • GE GLOBAL RESEARCH
    • STRATEGY
  • MAGFORCE NANOTECHNOLOGIES AG
    • PRODUCTS
    • STRATEGY
  • MERSANA THERAPEUTICS INC.
    • PRODUCTS
    • STRATEGY
  • MIV THERAPEUTICS INC
    • STRATEGY
  • NANOCARRIER CO., LTD.
    • PRODUCTS
    • STRATEGY
  • NANOFIBER SOLUTIONS
    • PRODUCTS
  • NANO INTERFACE TECHNOLOGY, INC
    • PRODUCTS
    • STRATEGY
  • NANO MED TECH
    • PRODUCTS
  • NANOPROBES, INC
    • STRATEGY
  • NANOSPHERE INC.
    • PRODUCTS
    • STRATEGY
  • NANOTHERAPEUTICS
    • STRATEGY
  • NOVARTIS INTERNATIONAL AG
    • PRODUCTS
    • STRATEGY
  • PHARMASOL CORP.
    • PRODUCTS
    • STRATEGY
  • SKYEPHARMA, PLC
    • PRODUCTS
    • STRATEGY
  • STARPHARMA HOLDINGS, LTD
    • PRODUCTS
    • STRATEGY
  • T2 BIOSYSTEMS INC.
    • PRODUCTS
    • PRODUCTS
    • STRATEGY
  • TALON THERAPEUTICS INC.
    • PRODUCTS
    • STRATEGY

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND DIAGNOSTIC IMAGING
  • TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY
  • TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT
  • TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS
  • TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS
  • TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING
  • TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD
  • TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS, THROUGH 2019 ($ MILLIONS)
  • TABLE 9 MAJOR NANOPARTICLE/NANOCRYSTAL DRUG REVENUES, THROUGH 2014
  • TABLE 10 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2019 ($ MILLIONS)
  • TABLE 11 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF NANOPARTICLES, THROUGH 2019 ($ MILLIONS) 2
  • TABLE 12 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION, THROUGH 2019 ($ MILLIONS)
  • TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS)
  • TABLE 14 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING SYSTEMS, THROUGH 2019 ($ MILLIONS)
  • TABLE 15 GLOBAL DISTRIBUTION OF NANOBIOTECHNOLOGY AND NANOMEDICINE COMPANIES
  • TABLE 16 NANOPARTICLE STRUCTURE AND PROPERTIES
  • TABLE 17 NANOPARTICLE SYSTEMS APPROVED FOR DRUG DELIVERY
  • TABLE 18 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME NANOTECHNOLOGY
  • TABLE 19 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS
  • TABLE 20 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT
  • TABLE 21 ETPN STRATEGIC RESEARCH AND INNOVATION AGENDA
  • TABLE 22 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS
  • TABLE 23 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE IN NANOPARTICLE DELIVERY SYSTEMS
  • TABLE 24 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS
  • TABLE 25 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS
  • TABLE 26 STANDARD ROUTES OF DRUG ADMINISTRATION
  • TABLE 27 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS
  • TABLE 28 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS
  • TABLE 29 NANOCRYSTAL DRUGS APPROVED BY THE FDA
  • TABLE 30 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY
  • TABLE 31 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC IMAGING
  • TABLE 32 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS
  • TABLE 33 FDA-APPROVED DRUGS FOR CANCER TREATMENT
  • TABLE 34 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES
  • TABLE 35 FDA-APPROVED NANOPARTICLE DRUGS FOR INFECTIOUS DISEASES
  • TABLE 36 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION MARKET
  • TABLE 37 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS
  • TABLE 38 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS
  • TABLE 39 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS
  • TABLE 40 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS
  • TABLE 41 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS
  • TABLE 42 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS
  • TABLE 43 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS
  • TABLE 44 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS)
  • TABLE 45 REGIONAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2019 ($ MILLIONS)
  • TABLE 46 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING, THROUGH 2019 ($ MILLIONS)
  • TABLE 47 DISTRIBUTION OF NANOPARTICLE DRUG CLINICAL TRIALS WITHIN DISEASE CATEGORIES
  • TABLE 48 CLINICAL TRIALS FOR NANOPARTICLE DRUGS FOR CANCER
  • TABLE 49 CLINICAL TRIALS FOR NANOPARTICLE DRUGS/PROCEDURES (NON-CANCER)
  • TABLE 50 CLINICAL TRIALS WITH NANOPARTICLE DRUGS (MISCELLANEOUS)
  • TABLE 51 RESPIRATORY SYNCYTIAL VIRUS NANOPARTICLE VACCINE CLINICAL TRIALS
  • TABLE 52 CLINICAL TRIALS FOR NANOPARTICLES FOR DIAGNOSTIC IMAGING
  • TABLE 53 NANOPARTICLE DRUGS/CARRIERS IN PRECLINICAL EVALUATION
  • TABLE 54 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER AND ACQUISITION ACTIVITIES
  • TABLE 55 GLOBAL PERCENTAGE OF PATENTS ISSUED BY GEOGRAPHY, THROUGH 2014
  • TABLE 56 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT AND DELIVERY
  • TABLE 57 U.S. PATENTS FOR NANOCRYSTALLINE DRUGS 167
  • TABLE 58 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICAL APPLICATIONS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, 2012-2019 ($ MILLIONS)
Back to Top